Interim Data Show Satraplatin Efficacy in Advanced Prostate Ca

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 10
Volume 15
Issue 10

GPC Biotech AG and Pharmion Corporation have announced positive results for the companies' oral platinum agent satraplatin in an interim analysis of the double-blind, randomized phase III registration trial.

MARTINSRIED, Germany—GPC Biotech AG and Pharmion Corporation have announced positive results for the companies' oral platinum agent satraplatin in an interim analysis of the double-blind, randomized phase III registration trial. The study, known as SPARC (Satraplatin and Prednisone Against Refractory Cancer), evaluated satraplatin plus prednisone vs placebo plus prednisone as second-line treatment in 950 patients with hormone-refractory prostate cancer. The study data show that improvements in progression-free survival (PFS) with satraplatin are highly significant (P < .00001). Patients who received satraplatin/prednisone had a 40% reduction in risk of disease progression (HR 0.6, 95% CI 0.5-0.7), compared with the prednisone/placebo patients.

The improvement seen in PFS in the satraplatin patients increased over time. Progression-free survival at the median (50th percentile) showed a 13% improvement (11 weeks vs 9.7 weeks for the controls). At the 75th percentile, the improvement was 89% (36 weeks vs 19 weeks). At 6 months, 30% of patients in the satraplatin arm had not progressed, compared with 17% in the control arm. At 12 months, 16% of patients on satraplatin had not progressed vs 7% of controls. All of these analyses were conducted on an intent-to-treat basis.

The improvement in progression-free survival in the satraplatin arm was not affected by the type of prior chemotherapy. In particular, the companies said, the improvement was seen equally for patients who had received prior docetaxel (Taxotere), as well as those who received other types of chemotherapy.

In accordance with the recommendation of the independent Data Monitoring Board for the SPARC trial, patients who have not progressed will continue to be treated, and all patients will be followed for overall survival. With approximately half of the patients from the trial still alive, the companies currently expect to have final overall survival results in the fall of 2007.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content